Kornimate/medical-research-clean huggingface dataset:
study of brain control of movement

Conditions: Movement Disorder; Healthy

Summary: this study will use transcranial magnetic stimulation to examine how the brain controls movement by sending messages to the spinal cord and muscles and what goes wrong with this process in disease. normal healthy volunteers between the ages of 18 and 65 years may be eligible to participate. in transcranial magnetic stimulation, an insulated wire coil is placed on the subject's scalp or skin. brief electrical currents are passed through the coil, creating magnetic pulses that stimulate the brain. during the stimulation, participants will be asked to tense certain muscles slightly or perform other simple actions. the electrical activity of the muscle will be recorded on a computer through electrodes applied to the skin over the muscle. in most cases, the study will last less than 3 hours.

the purpose of this study is to investigate the influence of voluntary inhibition of movement, using either negative motor imagery or go/nogo reaction task, on cortical inhibitory mechanisms. intracortical inhibition (ici) and silent period (sp) are two major cortical inhibitory mechanisms demonstrated by transcranial magnetic stimulation (tms). alterations in these inhibitory mechanisms have been extensively studied in various situations, but the influence of voluntary inhibition has not been elucidated yet. in normal volunteers, therefore, we plan to determine if voluntary inhibition of movement influences these cortical inhibitory mechanisms. the primary outcome measures would be any changes in motor evoked potential (mep) size and intracortical inhibition (ici) parameters.

Eligibility criteria:
volunteers who are greater than or equal to 18 years old. subjects must not have any medico-surgical illness. subjects must not have neurological illness. subjects must not have psychiatric illness. subjects must not be taking any medication with potential influence on nervous system function. subjects must not have a pacemaker. subjects must not have an implanted medical pump. subjects must not have a metal plate or a metal object in the skull or eye. subjects must not have a history of seizure disorder.

Keywords: transcranial magnetic stimulation motor cortex motor imagery reaction time cerebral inhibition healthy volunteer normal control
treatment of internal inflammatory root resorption using injectable prf revascularization technque

Conditions: Root Resorption

Summary: currently endodontics looks forward for regeneration rather than repair. regenerative endodontic therapy was limited to pulp revascularization of necrotic pulp in immature teeth , followed by mature teeth. recently pulp revascularization technique by induction of blood clot was applied in the treatment of inflammatory root resorption. so far, no clinical study for management of teeth with inflammatory internal root resorption by using injectable prf revascularization has been described in the literature. thus, this is the first clinical attempt to manage inflammatory root resorption in necrotic incisor teeth using injectable prf regenerative approach.

13 teeth in a total of 10 patients with inflammatory root resorption will be treated using revascualrization technique, iprf will be prepared and unjected in the canal after previous canal disinfection with calcium hydroxide for 2-4 weeks. cbct will be taken preoperative and 12 month follow up period, also clinical and radiographic follow uo will be considered every 3 months for 1 year.

Eligibility criteria:
inclusion criteria: * patients 13-30 years old * no sex predilection * medically free * suffering from internal inflammatory root resorption in permanent anterior mature teeth * associated with or without periapical radiolucency * no or grade i tooth mobility, and a pocket depth \<3 mm exclusion criteria: * old age * medically medically compromised patients

Keywords: pulp revascularization injectable platelet rich fibrin i-prf root resorption cbct
comparison of smoflipid to soy-based lipid reduction for cholestasis prevention in surgical neonates

Conditions: Cholestasis of Parenteral Nutrition

Summary: intestinal failure associated liver disease is a cholestatic liver disease associated with prolonged need for parenteral nutrition that can lead to such significant complications as liver failure. in the neonatal population, infants with history of intestinal resection and short bowel syndrome are at increased risk for this disease. the investigators plan to compare two possible lipid dosing preventative strategies including a composite, fish oil lipid and soy-based lipid reduction.

intestinal failure associated liver disease (ifald) is a cholestatic liver disease associated with prolonged need for parenteral nutrition. this disease can lead to such serious complications as liver failure and need for transplantation. in the neonatal population, short bowel syndrome, due to intestinal resection, is the most common cause of intestinal failure. while the exact cause is yet to be determined, it is felt the lipid component of parenteral nutrition is a large contributor to the development of this disease. currently, there is no standard preventative strategy to attempt to decrease the risk of ifald in the high risk, post-surgical neonatal population. the investigators aim to complete a randomized trial comparing two possible preventative strategies. one group will receive a composite lipid containing fish oil (smoflipid) and the other group will receive soy-based lipid at reduced dosing.

Eligibility criteria:
inclusion criteria: neonates with anticipated need for parenteral nutrition (based on primary physicians opinion) for greater than or equal to four weeks and one of the following diagnoses: * anatomic: neonate with intestinal atresia, omphalocele, gastroschisis, or volvulus with or without intestinal resection. * ischemic/perforation: neonates with spontaneous intestinal perforation or necrotizing enterocolitis requiring surgical intervention. exclusion criteria: * current weight less than 750 grams * ast or alt greater than 5 times the upper limit of normal within 2 weeks of enrollment * direct bilirubin greater than 2 mg/dl on any consecutive measurements 5 - 7 days apart within 2 weeks of enrollment * severe coagulopathy with inr greater than 95th percentile for age (\>1.7 at less than 5 days of age, \> 1.5 older than five days of age) * culture confirmed sepsis with positive blood, urine, or csf culture within 2 weeks of enrollment * renal failure requiring dialysis * cyanotic heart disease requiring prostaglandin therapy * hypertriglyceridemia (greater than 250mg/dl) at time of enrollment
bioequivalence study comparing a new 10 mg atorvastatin tablet to a 10 mg atorvastatin commercial tablet

Conditions: Hypercholesterolemia

Summary: • to determine whether new 10 mg atorvastatin tablets are bioequivalent to 10 mg commercial atorvastatin tablets (lipitor®).


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 18 and 55 years * body mass index (bmi) of 18 to 30 kg/m2; and a total body weight \>50 kg (110 lbs). exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at screening. * treatment with an investigational drug within 30 days or 5 half lives preceding the first dose of study medication.

Keywords: bioequivalence, pharmacokinetics, atorvastatin
safety and pharmacokinetics of n1539 in children 2 to <17 years of age following surgery

Conditions: Post Operative Pain

Summary: this study is an open-label, multicenter evaluation of safety and pharmacokinetics of n1539 in postoperative pediatric subjects aged 2 to \<17 years.


Eligibility criteria:
inclusion criteria: * male or female 2 to \<17 years of age before dosing on day 1 * eligible for elective surgery that will be performed according to standard surgical technique under appropriate anesthesia * be premenarche or have confirmed negative urine pregnancy testing before surgery on day 1, if an adolescent female of childbearing potential * willing and able to cooperate with all the requirements of the study; including providing appropriate informed consent/assent exclusion criteria: * have a known allergy or hypersensitivity to meloxicam, aspirin, other non-steroidal anti-inflammatory drugs (nsaids), or any excipient of n1539 * have a known bleeding disorder that may be worsened with the administration of an nsaid * be undergoing cardiothoracic surgery * has used meloxicam within 7 days before the surgical procedure on day 1 * has any clinically significant medical history or clinical manifestations of significant disease or any other condition that increases the risk associated with the subject's participation in the study or compromises the scientific objectives of the study.

Keywords: meloxicam pediatric
the effects of neuraminidase inhibitor oseltamivir in patients with chronic heart failure

Conditions: Heart Failure

Summary: heart failure (hf) is a complex syndrome with increasing incidence and high rates of mortality and hospitalization. although inhibitors of angiotensin converting enzyme (ace), β-blockers and aldosterone-receptor blockers have improved the treatment of heart failure, mortality of hf remains unacceptably high. recently, we identified a key metabolite n-acetylneuraminic acid (neu5ac) increased in the plasma of patients with heart failure. also, elevated plasma neu5ac, independent of other traditional risk factors, is associated with poor prognosis in patients with hf in long-term follow up. neu5ac levels, the most common sialic acid in mammals, generated from sialylated glycoconjugates by neuraminidase. neu5ac and its regulatory enzyme neuraminidase play a key role in heart failure. we found neuraminidase inhibitor could reduce neu5ac levels and improve heart failure in mice model, providing opportunity for a novel therapeutic strategy in hf. neuraminidase inhibitor oseltamivir is also an old anti-influenza drug. using oseltamivir may be a new therapeutic strategy in heart failure. based on above information, we designed the randomized, open-label, blank-controlled study in patients with chronic hf to receive either oseltamivir or placebo, in addition to standard hf therapy to identify the effect of oseltamivir on serum neu5ac level in patients with heart failure and assess the clinic outcomes of level in patients with heart failure using oseltamivir.


Eligibility criteria:
inclusion criteria: 1. 18 of age or older, regardless of gender; 2. patients with nyha ii-iv, lvef less than 40%; 3. levels of nt-probnp more than 450 pg/ml 4. willing to participate in this study and sign an informed consent, and receive follow-up contact for at least 6 months. exclusion criteria: 1. onset of acute myocardial infarction within the last 1 month; 2. had cardiac surgery or onset of cerebrovascular accident within the last 6 months; 3. plan to have cardiac transplantation or crt, or already having crt therapy; 4. females with pregnancy or plan to have pregnancy; 5. have participate in any other clinical trial within the last 3 months; 6. severe neurological disorders (alzheimer's disease, progressive stage of parkinson's syndrome), disabilities of lower limbs or deaf-mute; 7. had a history of tumour, or precancerous lesions confirmed by pathological tests (ductal carcinoma in situ, cervical dysplasia, etc.); 8. had malignant tumours (by physical examinations, x-ray, type-b ultrasonic imaging or other methods), or had hyperplastic glands or adenoma which possess endocrine activity and affect cardiac or endocrine functions (pheochromocytoma, goitre, etc.); 9. the subjects who refuse to comply with the items of the research protocol; 10. the subjects who are not available to fulfil the follow-up plan (due to project management or other reasons), according to the judgement of researchers.

Keywords: heart failure neuraminidase inhibitor oseltamivir neu5ac ntprobnp
role of new high resolution ultrasonographic modalities for diagnosis of fetal nervous system anomalies

Conditions: Ultrasound Therapy; Complications; Anomaly; Central Nervous System Diseases

Summary: the fetal cns screening examination during the mid-trimester scan in low-risk pregnancies should include evaluation of the fetal head and spine, using transabdominal sonography. evaluation of two axial planes allows visualization of the relevant cerebral structures to assess the anatomic integrity of the fetal brain.these planes are commonly referred to as the transventricular and transcerebellar planes. a third plane, the so-called transthalamic plane, is frequently added, mostly for the purpose of biometry. structures that should be noted in the routine examination include the lateral ventricles, the cerebellum, the cisterna magna, and the cavum septi pellucidi (csp). head shape and brain texture should also be noted on these views.

the neural system malformation is one of the more common congenital anomalies encountered in pregnancy. they represent about 0.3-1 percent of all live births. during a prenatal anomaly scan, detection of cns malformations is important, especially since these anomalies have a poor prognosis and are also associated with genetic syndromes or chromosomal anomalies. such malformations have clinical importance because they are associated with high rates of morbidity and mortality, influencing the neurocognitive and motor development of the survivors, who may have lifelong sequelae. thus, it's extremely important to assess the fetal cns during the prenatal period in order to identify any changes in its development and give appropriate advice to parents regarding pregnancy follow-up. also, it is vital to explore options for fetal therapy and the timing/type of delivery, as well as postnatal treatment and prognosis. the fetal cns screening examination during the mid-trimester scan in low-risk pregnancies should include evaluation of the fetal head and spine, using transabdominal sonography. evaluation of two axial planes allows visualization of the relevant cerebral structures to assess the anatomic integrity of the fetal brain.these planes are commonly referred to as the transventricular and transcerebellar planes. a third plane, the so-called transthalamic plane, is frequently added, mostly for the purpose of biometry. structures that should be noted in the routine examination include the lateral ventricles, the cerebellum, the cisterna magna, and the cavum septi pellucidi (csp). head shape and brain texture should also be noted on these views.

Eligibility criteria:
1. inclusion criteria: 2. suspicion of cns or spinal malformation at routine screening ultrasound 3. suspicion of cns or spinal malformation at nuchal translucency scan 4. family history of inheritable cns spinal malformations 5. previous pregnancy complicated by fetal brain or spinal malformation 6. fetus with congenital heart disease 7. monochorionic twins 8. suspected congenital intrauterine infection exposure to teratogens known to affect neurogenesis exclusion criteria: * low risk pregnancy
comparison of the effects of oral stimulation and non-nutritive sucking practices

Conditions: Premature; Nutrition Disorders; Sucking Behavior

Summary: this study, it was aimed to compare the effects of oral stimulation and non-nutritive sucking practices on the transition to full oral feeding in babies with a gestational age of 26-32 weeks. non-oral feeding methods are frequently used in babies born prematurely since sucking and sucking-swallowing coordination have not yet developed. while some premature babies gain the sucking and swallowing reflexes faster, some of them cannot develop this reflex for a long time, so the length of hospital stay is prolonged. all infants who can be fed completely enterally (pma \>29 weeks) will be randomized into 4 groups as oral stimulation (group 1), pacifier (group 2), oral stimulation + pacifier (group 3), and control group by using a stratified blocked randomization method with a block size of 4. stratification on ga (26-27, 28-29, 30-32 weeks ga) was used to ensure that the groups had similar gestational age distribution. the time of the patients to start breastfeeding and the length of hospital stay (days) will be compared.


Eligibility criteria:
inclusion criteria: * preterm babies born between 26-32 weeks (including 26 and 32 weeks) exclusion criteria: * babies with congenital anomalies * babies born with asphyxia * babies with major gis anomalies * babies who have undergone major gis surgery

Keywords: sucking oral stimulation premature baby
safety and blood level study of unit dose budesonide

Conditions: Asthma

Summary: the purpose of this study is to evaluate the tolerability and pharmacokinetics of three doses of map0010 (unit dose budesonide) compared with pulmicort respules® (budesonide) in healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy adult volunteers, aged 18-50 years * bmi less than 30 kg/m2 * non smoker (currently and \<10 pack years total if ex-smoker) exclusion criteria: * any use of corticosteroid in previous 4 weeks * pregnancy/lactation * significant blood donation (or testing) in previous 8 weeks

Keywords: pediatric asthma
myocardial infarction prescription duration adherence study

Conditions: Medication Adherence

Summary: quasi-experimental, controlled interrupted time series design, evaluating the impact of the intervention at hamilton health sciences (hhs) where standardized prescriptions and education will be provided and st joseph's hospital (sjh) and niagara health services (nhs) where education alone will be provided, with remaining ontario cardiac sites as a concurrent control group.

the overarching goal of this study is to reduce the morbidity and mortality of post-mi patients through improved long-term cardiac medication adherence. the specific objectives include: 1. assess the impact on long-term cardiac medication adherence following the implementation of a standardized increase in discharge prescription length to 90-days with 3 repeats in post-mi patients as compared to education alone and usual care; 2. assess the cost implications of the intervention as compared to usual care; 3. compare clinical outcomes between longer (\>60 days) versus shorter prescription durations; 4. collect baseline information to inform a multi-centre interventional study (i.e., simple monthly proportions of 1-year adherence by hospitals in ontario). intervention:1. policy change implementing a standardized discharge prescription form available on all wards where mi patients are managed at hhs that includes a 90-day supply with 3 repeats for all cardiac medications, and education alone provided at sjh and nhs 2. educational materials will be disseminated to all involved health care providers (e.g., physicians, residents, nurses) at the start of the intervention period to ensure the new discharge prescriptions are understood and used. furthermore, extensive outreach to community pharmacies in lhin iv will be undertaken with help from ontario pharmacists' association (opa) and ontario pharmacy evidence network (open). 3. education (e.g., emails, mail-outs, site visits) will recur every 3-4 months during the intervention period. furthermore, monthly monitoring will ensure standardized prescription forms and point of care reminders are implemented at all intervention sites. the intervention group will be exposed to this intervention post-mi and include all eligible patients at hhs/sjh/nhs in the 6-months post-intervention implementation.

Eligibility criteria:
inclusion criteria: * use of ontario drug benefits (odb-age \>65 years, social assistance, and disability); * cardiac catheterization during an index admission with an mi; * evidence of obstructive coronary artery disease; * discharged alive * ontario residents (ontario, canada) exclusion criteria: * none

Keywords: myocardial infarction adherence medication
new preclinical and clinical approaches to mesothelioma

Conditions: Mesothelioma

Summary: this study protocol involves the coordination between uo1 (irccs san raffaele hospital) and uo2 (istituto nazionale tumori di napoli - irccs g. pascale) to explore the role of hmgb1 and cxcr4 in cancer treatment and metastasis. uo1 focuses on the role of hmgb1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible hmgb1 inhibitors for cancer therapy. uo2 specializes in cxcr4's role in cancer, developing cxcr4 antagonists, and tracking cxcr4-dependent metastasis. the hypothesis is that targeting hmgb1 and cxcr4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.

this is a multicentric cross-sectional observational study with an additional blood volume collected during blood sampling performed for normal clinical practice. the enrollment will take

Eligibility criteria:
inclusion criteria: * patients with mesothelioma: clinical suspicion or histologically confirmed diagnosis of pleural mesothelioma. * candidates for surgical intervention. * age 18 years or older. it is possible to include both male and female patients, male and female patients of reproductive age, as well as breastfeeding women. * capacity to comprehend the study nature and provide autonomously informed consent. control group patients: * absence of pleural mesothelioma but presence of other histologically confirmed diseases (neoplastic, inflammatory, or infectious). * candidates for surgical intervention. * age 18 years or older. it is possible to include both male and female patients, male and female patients of reproductive age, as well breastfeeding women. * ability to understand the study nature and provide autonomously informed consent. if the patient's diagnosis, whether provisional or definitive, does not confirm the clinical suspicion, they will not undergo further evaluation in the study. exclusion criteria: * lack of biopsy material. * pregnancy. * unwillingness to sign the informed consent.